【Chair】

Professor , Department of Multipl e Sclerosis Therapeutics, Fukushima Medical University School of Medicine, and Director, Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama , Japan

Kazuo Fujihara, MD

CD19-targeted B-cell depleting Therapy

Impact in the NMOSD World

【Speaker1】

Associate Professor in Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine

Hirofumi Ochi, MD, PhD

The long-term benefits of Inebilizumab

【Speaker2】

Head of Department of Neurology and Division of Clinical Research, Professor of Department of Cancer Biomedical Science, Graduate School of Cancer Science & Policy National Cancer Center, Goyang, Korea

Ho Jin Kim, MD, PhD